# Adin vs GLP1 Tracker

The clearest difference is monetization model: Adin at free with in-app purchases against GLP1 Tracker's subscription. Adin also leads on device support (3 vs 1) and ratings volume (3 vs 1). GLP1 Tracker's advantage is update cadence (every 3 days vs every 11 days). On price, rating, ads and in-app purchases there is nothing between them.

Both are free to download. Adin sells 1 in-app purchase, starting at $7.99 per month and GLP1 Tracker sells 4 in-app purchases, starting at $9.99 per month. Whichever you choose, the download price is not the number that matters.

On the App Store both sit at effectively the same score — 5.0 for Adin against 5.0 for GLP1 Tracker. Both are backed by a comparable volume of ratings — 3 and 1 respectively.

Adin ships an update every 11 days, GLP1 Tracker every 3 days. The most recent releases landed on October 18, 2026 and October 19, 2026 respectively.

## The numbers

| Metric | Adin | GLP1 Tracker |
| --- | --- | --- |
| Price | Free | Free |
| Rating | [5.0 (3 ratings)](https://appshunter.io/ios/app/adin/id6761314646/reviews) | [5.0 (1 ratings)](https://appshunter.io/ios/app/glp1-tracker-veya/id6797665408/reviews) |
| Number of ratings | **3** | 1 |
| Positive reviews | 100.0% of reviews | — |
| In-app purchases | Yes | Yes |
| Ads | No | No |
| Update frequency | Every 11 days | **Every 3 days** |
| Monetization | **Free with in-app purchases** | Subscription |
| Size | 13 MB | 83 MB |
| Requires iOS | **14.0** | 16.4 |
| Devices | **iPhone, iPad, iPod** | iPhone |
| Age rating | 17+ | 12+ |
| Developer | [ProofMed AI](https://appshunter.io/developer/1888818150) | [Ad Astra Studios](https://appshunter.io/developer/6797665410) |

## What reviewers say

### Adin

[App page](https://appshunter.io/ios/app/adin/id6761314646)

This health app uses advanced AI to provide personalized health insights, condition management, and medication tracking. It offers evidence-based guidance, differential diagnoses, and nutrition planning tailored to your specific health profile.

**Highlights:** Interactive symptom analysis with confidence scores, Personalized condition management plans, Medication tracking and drug interaction alerts, Contextual lab result interpretation, Condition-aware nutrition planning

**Features:** macOS Compatibility, Vision Pro support

**In-app purchases (1)**

| Purchase | Price | Billing |
| --- | --- | --- |
| Adin Premium | $7.99 | per month |


### GLP1 Tracker

[App page](https://appshunter.io/ios/app/glp1-tracker-veya/id6797665408)

This app helps users track their GLP-1 medication doses, side effects, and weight progress. It provides reminders for injections or pills and visual aids for rotating injection sites. The app focuses on simplifying the GLP-1 routine and offering insights into personal consistency.

**Highlights:** Track GLP-1 shots and pills, Log medication amount and injection site, Set custom dose reminders, Visualize injection site rotation, Log and rate side effects, Track personal weight goals, Generate appointment summaries

**In-app purchases (4)**

| Purchase | Price | Billing |
| --- | --- | --- |
| Veya Premium | $9.99 | per month |
| Veya Premium | $9.99 | per month |
| Veya Premium | $59.99 | per year |
| Veya Premium | $59.99 | per year |


## Frequently asked questions

### Is Adin free?

Adin is free to download, with in-app purchases available.

### Is GLP1 Tracker free?

GLP1 Tracker is free to download, with in-app purchases available.

### Which has better reviews, Adin or GLP1 Tracker?

Adin and GLP1 Tracker are both rated 5.0 out of 5 on the App Store, from 3 and 1 ratings respectively.

### Do Adin or GLP1 Tracker have ads?

Neither Adin nor GLP1 Tracker shows ads.

### Which is updated more often, Adin or GLP1 Tracker?

Adin ships an update every 11 days, and GLP1 Tracker every 3 days. Most recently, Adin was updated on October 18, 2026 and GLP1 Tracker on October 19, 2026.

---

*Compared by [AppsHunter](https://appshunter.io/) from daily US App Store data. Review summaries are generated from verbatim App Store reviews.*